B3 seeks to develop novel nanoparticle (NP)-based therapeutics which bypass the blood brain barrier (BBB). Direct delivery into the CNS achieved via intrathecal infusion or convection-enhanced delivery (CED). Our approach can be applied to an array of small molecules and nucleic acid-based therapeutics, and our therapeutic strategies have the potential to treat a wide range of primary CNS tumors and metastases. We have assembled a world class team of founders with a track record of translating high impact science into the clinic. In vivo proof-of-concept data supports the feasibility and efficacy of NP-encapsulated DNA repair inhibitors, and our foundational IP will be exclusively licensed from Yale and UConn. We are currently raising Seed round funding to support key in vivo studies for candidate nomination and platform expansion.